Search
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … [L46516] It is administered subcutaneously and is currently being evaluated as a monotherapy and in combination for the treatment of a variety of hematologic malignancies.
Azaperone
go.drugbank.com/drugs/DB11376InvestigationalVet approvedAt the same time, the agent generally does not see equine use as particular adverse reactions may happen. More rarely it may be used in humans as an antipsychotic drug, but this is uncommon. … It is subsequently employed predominantly as a veterinary tranquilizer and mainly for pigs and elephants.
Categories: Dopamine D2 Receptor AntagonistsBentiromide
go.drugbank.com/drugs/DB00522ApprovedWithdrawnBentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy.
Categories: Compounds used in a research, industrial, or household settingFiruglipel
go.drugbank.com/drugs/DB19506InvestigationalFiruglipel has a monoisotopic molecular weight of 467.19 Da. … Firuglipel is a small molecule drug. Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin).
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigationalAs an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and inhibiting protein and DNA synthesis. … [A1407] Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA, azacytidine has been used mainly used in the treatment of myelodysplastic syndromes (MDS) and acute
Synonyms: 4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-oneArgatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalArgatroban is a direct, selective thrombin inhibitor. … Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexChlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnDue to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. … Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
Products: ANTI-D TABLET 250 mgPomaglumetad methionil
go.drugbank.com/drugs/DB05096InvestigationalLY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022]. … with first-line therapies, putting them in a risk for poor outcomes and creating a significant clinical challenge [A31818].
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class